HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients

No data are available on the role of HER2 overexpression in predicting the efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. We retrospectively evaluated this role in patients enrolled in a phase III study comparing standard FEC21 (5-fluorouracil, epiru...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Mastro, L, Bruzzi, P, Nicolò, G, Cavazzini, G, Contu, A, D'Amico, M, Lavarello, A, Testore, F, Castagneto, B, Aitini, E, Perdelli, L, Bighin, C, Rosso, R, Venturini, Marco
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361477/
https://www.ncbi.nlm.nih.gov/pubmed/15970926
http://dx.doi.org/10.1038/sj.bjc.6602660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361477/
https://www.ncbi.nlm.nih.gov/pubmed/15970926
http://dx.doi.org/10.1038/sj.bjc.6602660

Ejemplares similares